89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Question-and-Answer SessionRohan, maybe to start, I would love to just pass the mic to you ask for an update on progress. You have several ongoing studies, all Phase III at the company in MASH and in SHTG. And then we'll dive into Q&A across the board on all of them.Rohan PalekarCEO & Director Sure. So Steve, first of all, thanks for having us here. As you mentioned, we're incredibly excited about the progress we're making with pegozafermin, our FGF21 analog. And we have 3 ongoing studies. So we have our SH ...